肖 婧,张海泉,王志勇.501例垂体瘤患者临床特征及预后分析[J].肿瘤学杂志,2017,23(7):602-605. |
501例垂体瘤患者临床特征及预后分析 |
Analysis of Clinical Features and Prognosis of 501 Patients with Pituitary Tumor |
投稿时间:2016-12-07 |
DOI:10.11735/j.issn.1671-170X.2017.07.B008 |
|
|
中文关键词: 垂体瘤 临床特征 预后 |
英文关键词:pituitary tumor clinical features prognosis |
基金项目:湖北省卫生计生委青年科技人才项目(QJX2012-40) |
|
摘要点击次数: 1831 |
全文下载次数: 532 |
中文摘要: |
摘 要: [目的] 探讨垂体瘤患者的临床特征和预后分析。[方法] 对2006年1月至2015年12月就诊于襄阳市中心医院的501例垂体瘤术后患者的临床资料进行回顾性分析。[结果] 男性患者的发病年龄明显高于女性(46.7±13.2岁 vs 45.0±12.5岁;t=2.994,P=0.003)。肿瘤大小0.5~8.0cm。其中大腺瘤最为多见(86.0%),其次为巨大腺瘤 (8.6%),而微腺瘤的检出率仅为5.4%;不同影像学检查方法与不同大小垂体瘤检出率之间差异有统计学意义(χ2=7.085,P=0.029)。MRI对微腺瘤的检出率(77.8%)高于CT的检出率(22.2%)。垂体瘤临床症状以头晕、头痛及呕吐为主(46.1%),其次为视力下降、视物模糊、视野缺损(35.7%)。术前诊断以多激素混合瘤最多 (60.1%),其次为促甲状腺激素瘤(TSH) (16.6%),促性腺激素瘤(LH/FSH)最低(0.6%),术后病理诊断以泌乳素瘤(PRL)最多(33.1%),其次为多激素混合瘤(21.6%)。生存分析结果显示,患者10年总体生存率为70.27%,其中,无功能性腺瘤与功能性腺瘤的10年生存率分别为66.72%与75.31%。[结论] 垂体瘤多发于41~70岁人群,以大腺瘤最为多见,MRI对微腺瘤的检出率高于CT。患者术后生存情况相对较好,其中功能性腺瘤患者的生存情况优于无功能性腺瘤患者,应加大对无功能腺瘤患者的临床关注。 |
英文摘要: |
Abstract:[Objective] To explore the clinical features and prognosis of pituitary tumor. [Methods] The records of 501 cases with pituitary tumor at Xiangyang Central Hospital from January 2006 to December 2015 were retrospectively reviewed. [Results] The age of onset of male patients was significantly higher than that of female(46.7±13.2 vs. 45.0±12.5;t=2.994,P=0.003). The size of tumor was 0.5~8.0cm,among which the most common was denoma(86%),followed by huge adenoma(8.6%),while the micro adenoma detection rate was 5.4%. There was statistical significance testing methods and different imaging of pituitary tumor detection rate between different sizes (χ2=7.085,P=0.029),the detection rate of MRI micro adenoma(77.8%) was higher than that CT(22.2%). The clinical symptoms were dizziness,headache and vomiting(46.1%),followed by decreased vision,blurred vision and visual field defects(35.7%). According preoperative diagnosis,multiple hormone mixed tumor topped first(60.1%),followed by thyroid stimulating hormone(TSH) (16.6%),gonadotropin(LH/FSH) were the last(0.6%). Postoperative pathological diagnosis showed prolactinoma(PRL) accounted for 33.1%,followed by mixed tumor hormone(21.6%). Survival analysis indicated that the overall survival rate was 70.27%,the survival rate of non-functional pituitary tumor and functional pituitary tumor were 66.72% and 75.31%,respectively. [Conclusion] Pituitary tumor is mostly seen in the 41~70 age group,large adenoma is the most common type. The detection of MRI for micro adenoma is higher than CT. More clinical intervention should be taken to treat effectiveness of non- functional pituitary tumor patients. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |